IT-Nov 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. IT-Nov 200 is primarily prescribed for infections caused by dermatophytes, yeasts, and molds, including onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability when taken with food, facilitating effective systemic absorption. Dosage and duration of therapy should be individualized based on the severity and type of infection, patient response, and clinical judgment. Caution is advised in patients with hepatic impairment or congestive heart failure, and liver function tests should be monitored during prolonged therapy. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 enzymes, necessitating careful review of concomitant medications. Common adverse effects include gastrointestinal disturbances, headache, and rash, while rare but serious adverse events may involve hepatotoxicity and cardiac effects. IT-Nov 200 Capsule should be used under medical supervision to ensure safe and effective antifungal treatment.